ZELTIQ Aesthetics, Inc. (Nasdaq: ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced the introduction of CoolCurve+, the newest addition to the applicator platform for the CoolSculpting® System, at the American Society for Dermatologic Surgery (ASDS) annual meeting in Atlanta. CoolCurve+ is anatomically designed with curved cooling plates to enhance fit and tissue draw on the body.
“We are pleased to expand our applicator platform and introduce this versatile addition to doctors to help them better customize procedure plans and optimize outcomes for their patients,” said Mark Foley, President and Chief Executive Officer.
In a recent assessment study conducted on 15 patients using the CoolCurve+ applicator, 36 percent more patients, who previously did not have adequate tissue draw due to their body shape, could be treated successfully with the CoolCurve+. Of all patients in the study, 73 percent experienced better fit and 80 percent experienced better tissue draw.1 In a separate performance study with 25 patients who received treatment with the CoolCurve+, patient feedback revealed 92 percent satisfaction and 100 percent who would recommend CoolSculpting with the CoolCurve+ applicator.2
“ZELTIQ is continually exploring ways to innovate the CoolSculpting procedure, as demonstrated by the new CoolCurve+ applicator,” said Michael Kaminer, MD, Managing Partner of SkinCare Physicians® in Chestnut Hill, Mass. “That commitment to excellence benefits both my patients and practice.”
“Since I started offering the procedure in 2009, CoolSculpting consistently drives new patients to my practice and CoolCurve+ now gives me the ability to treat an even broader base of patients with different body shapes,” said W. Grant Stevens, MD, FACS, Medical Director of Marina Plastic Surgery Associates in Marina Del Rey, Calif.
More than 400,000 CoolSculpting treatments have been performed worldwide. CoolSculpting results in an undeniable reduction of fat in the treated areas, and patients can start to see results as soon as three weeks following treatment, with the most dramatic results occurring over a period of two to four months in most patients. Every patient case is unique which is why ZELTIQ recommends a customized procedure plan as part of the initial consultation. After the initial treatment is complete, patients can attain further reductions with additional treatments, resulting in even more fat loss.
CoolSculpting® is a non-surgical, clinically proven procedure designed to selectively reduce fat bulges in problem areas using a patented cooling technology. Cleared by the FDA for non-invasive fat reduction in the abdomen and flank, it is a procedure that gently cools unwanted fat cells in the body to induce a natural, controlled elimination of fat cells. It is designed to reduce fat bulges in treated areas of the body without harming surrounding tissue. CoolSculpting is available through an elite network of CoolSculpting Centers worldwide. Dermatologists, plastic surgeons and leading aesthetic specialists that offer CoolSculpting can be found at www.coolsculpting.com.
About ZELTIQ Aesthetics, Inc.
ZELTIQ® Aesthetics, Inc. (Nasdaq: ZLTQ) is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ’s first commercial product, the CoolSculpting® System, is designed to selectively reduce stubborn fat bulges that may not respond to diet or exercise. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. CoolSculpting utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer within a treated fat bulge without requiring the patient to diet or exercise.
1, 2 Data on file.